Inactive Instrument

News CVTX

Stocks

US1266671049

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

All News

Mentions Relevance

-1-11-29	CV THERAPEUTICS : to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008	PR
-1-11-29	CV THERAPEUTICS : Announces License Agreement for Ranexa(R) in Europe With Menarini Group	PR
-1-11-29	CV THERAPEUTICS : Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases	PR
-1-11-29	CV THERAPEUTICS : Reports Option Grants Under Nasdaq Marketplace Rule 4350	PR
-1-11-29	CV THERAPEUTICS : Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxation in Study of Patients With Long QT Syndrome	PR
-1-11-29	CV THERAPEUTICS : Receives European Approval for the Brand Name Ranexa(R)	PR
-1-11-29	CV THERAPEUTICS : Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award	PR
-1-11-29	CV THERAPEUTICS : CVT Announces That FDA Continues to Review Ranexa(R) Applications	PR
-1-11-29	CV THERAPEUTICS : to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008	PR
-1-11-29	CV THERAPEUTICS : Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina	PR
-1-11-29	CV THERAPEUTICS : Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)	PR
-1-11-29	CV THERAPEUTICS : Reports Option Grants Under Nasdaq Marketplace Rule 4350	PR
-1-11-29	Cv Therapeutics : European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina	PR
-1-11-29	Cv Therapeutics : CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday, April 25, 2008	PR
-1-11-29	Cv Therapeutics : CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results	PR
-1-11-29	Cv Therapeutics : CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350	PR
-1-11-29	Cv Therapeutics : CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology	PR
-1-11-29	Cv Therapeutics : CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008	PR
-1-11-29	Cv Therapeutics : CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008	PR
-1-11-29	CV THERAPEUTICS : CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer	PR
-1-11-29	CV THERAPEUTICS : Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer	PR
-1-11-29	CV THERAPEUTICS : CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal	PR
-1-11-29	CV THERAPEUTICS : Statement on Unsolicited Proposal From Astellas	PR
-1-11-29	CV THERAPEUTICS : FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c	PR

No results match your criteria

All News Broker Recommendations Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Unlock them now!